Antimicrobial resistance point-of-care testing for gonorrhoea treatment regimens: cost-effectiveness and impact on ceftriaxone use of five hypothetical strategies compared with standard care in England sexual health clinics by Harding-Esch, E et al.
1www.eurosurveillance.org
Research
Antimicrobial resistance point-of-care testing for 
gonorrhoea treatment regimens: cost-effectiveness and 
impact on ceftriaxone use of five hypothetical strategies 
compared with standard care in England sexual health 
clinics
Emma M Harding-Esch1,2, Susie E Huntington³ , Michael J Harvey³ , Georgie Weston³ , Claire E Broad1 , Elisabeth J Adams3 , S Tariq 
Sadiq1,2,4
1. Applied Diagnostic Research and Evaluation Unit, Institute for Infection and Immunity, St George’s University of London, 
London, United Kingdom
2. National Infection Service, Public Health England, London, United Kingdom
3. Aquarius Population Health, London, United Kingdom
4. St George’s University Hospitals NHS Foundation Trust, London, United Kingdom
Correspondence: S Tariq Sadiq (ssadiq@sgul.ac.uk)
Citation style for this article: 
Harding-Esch Emma M , Huntington Susie E , Harvey Michael J , Weston Georgie , Broad Claire E , Adams Elisabeth J , Sadiq S Tariq . Antimicrobial resistance point-
of-care testing for gonorrhoea treatment regimens: cost-effectiveness and impact on ceftriaxone use of five hypothetical strategies compared with standard care in 
England sexual health clinics. Euro Surveill. 2020;25(43):pii=1900402. https://doi.org/10.2807/1560-7917.ES.2020.25.43.1900402
Article submitted on 21 Jun 2019 / accepted on 22 Apr 2020 / published on 29 Oct 2020
Background: Widespread ceftriaxone antimicrobial 
resistance (AMR) threatens Neisseria gonorrhoeae (NG) 
treatment, with few alternatives available. AMR point-
of-care tests (AMR POCT) may enable alternative 
treatments, including abandoned regimens, sparing 
ceftriaxone use. We assessed cost-effectiveness of 
five hypothetical AMR POCT strategies: A-C included 
a second antibiotic alongside ceftriaxone; and D and E 
consisted of a single antibiotic alternative, compared 
with standard care (SC: ceftriaxone and azithromycin).
Aim: Assess costs and effectiveness of AMR POCT 
strategies that optimise NG treatment and reduce 
ceftriaxone use. Methods: The five AMR POCT treat-
ment strategies were compared using a decision tree 
model simulating 38,870 NG-diagnosed England 
sexual health clinic (SHC) attendees; A micro-costing 
approach, representing cost to the SHC (for 2015/16), 
was employed. Primary outcomes were: total costs; 
percentage of patients given optimal treatment (regi-
mens curing NG, without AMR); percentage of patients 
given non-ceftriaxone optimal treatment; cost-effec-
tiveness (cost per optimal treatment gained). Results: 
All strategies cost more than SC. Strategy B (azithro-
mycin and ciprofloxacin (azithromycin preferred); dual 
therapy) avoided most suboptimal treatments (n = 48) 
but cost most to implement (GBP 4,093,844 (EUR 
5,474,656)). Strategy D (azithromycin AMR POCT; mon-
otherapy) was most cost-effective for both cost per 
optimal treatments gained (GBP 414.67 (EUR 554.53)) 
and per ceftriaxone-sparing treatment (GBP 11.29 
(EUR 15.09)) but with treatment failures (n  =  34) and 
suboptimal treatments (n  =  706). Conclusions: AMR 
POCT may enable improved antibiotic stewardship, but 
require net health system investment. A small reduc-
tion in test cost would enable monotherapy AMR POCT 
strategies to be cost-saving.
Introduction
Antimicrobial resistance (AMR) has developed to every 
class of antibiotic used for treatment of the bacterial 
sexually transmitted infection (STI)  Neisseria gonor-
rhoeae  (NG) [1], with increasing reports of multidrug-
resistant strains [2]. NG, the second most prevalent 
bacterial STI globally [3], is associated with serious 
long-term reproductive health complications if left 
untreated.
World Health Organization (WHO) guidelines [4] rec-
ommend a treatment regimen that treats at least 
95% of circulating NG strains, as monitored through 
antibiotic surveillance programmes such as Public 
Health England’s national Gonococcal Resistance to 
Antimicrobials Surveillance Programme (GRASP) [1]. 
Dual therapy with ceftriaxone and azithromycin is 
recommended in Europe [5], and was in the United 
Kingdom (UK) until 2019 [6] when it was replaced with 
1  g ceftriaxone monotherapy due to the emergence of 
azithromycin resistance [7]. AMR to ceftriaxone, an 
extended-spectrum cephalosporin, is the most urgent 
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threat [8,9] with few practical alternatives immediately 
available if widespread resistance develops.
Rapid diagnostics have been identified as a key 
approach to tackling AMR [10]. Rapid tests are those 
that have a two-hour turnaround, whereas point-of-care 
tests (POCTs) enable the test to be conducted, results 
obtained and treatment performed in the same clinical 
visit [11]. A principal feature of an NG AMR diagnostic 
is to assess antibiotic susceptibility at the time of NG 
diagnosis. A test that combines both NG diagnosis and 
AMR prediction at the point-of-care (AMR POCT) would 
allow the selection of appropriate treatment regimens 
for considerable numbers of NG infections, including 
safe use of antimicrobials which have been abandoned 
for widespread use due to circulating resistance, but 
which would be effective for a substantial proportion 
of infections [12]. For example, in the UK in 2018, 60% 
of NG infections were susceptible to ciprofloxacin, 90% 
to azithromycin and 88% to penicillin [1]. The ability to 
use these antibiotics to treat NG may in turn reduce 
AMR selection pressure on ceftriaxone [13].
Rapid tests are already being used for NG in some sex-
ual health clinics (SHC) [14]. While laboratory-based 
NG fluoroquinolone susceptibility tests exist [15], rapid 
NG AMR tests are in development and being clinically 
evaluated. One such test is an NG fluoroquinolone 
susceptibility AMR POCT, developed within the Precise 
Study [16] using the io platform (Binx Health Limited 
(formerly Atlas Genetics), Boston, United States (US)) 
already CE-marked for  Chlamydia trachomatis  (CT) 
detection [12,17]. Costs and short-term clinical impacts 
of these tests are used in procuring sexual health ser-
vices provision for a region (known as sexual health 
commissioning in England) and adoption into SHC 
decisionmaking [18].
In this analysis, we assessed the cost-effectiveness 
in English SHC of five hypothetical AMR POCT strat-
egies for the treatment of NG, which enable use of 
ciprofloxacin and/or azithromycin, either alongside, 
or as an alternative to, ceftriaxone. Potential diag-
nostic resistance-determinants of these antibiot-
ics are small in number (gyrA  for ciprofloxacin;  23S 
rRNA  and  mtrCDE  transporter for azithromycin), are 
relatively well-understood, and their absence predictive 
of susceptibility (particularly for ciprofloxacin). The 
development of molecular AMR POCTs for detection 
of these determinants are thus technically feasible 




We compared standard care (SC) for NG treatment in 
the UK (at the time of investigation, ceftriaxone 500 mg 
and azithromycin 1 g dual therapy [6]) with five differ-
ent AMR POCT strategies (Box,  Supplementary Figure 
S1), where the AMR POCT was used as a reflex test to 
inform antibiotic selection irrespective of which test 
was used to diagnose NG initially. The AMR POCT strat-
egies were chosen to either facilitate optimised choice 
Box  
Summary of antimicrobial resistance point-of-care test strategies
Standard care
Standard care with dual therapy of intramuscular ceftriaxone (500 mg) and oral azithromycin (1 g single dose).
Dual therapy, including ceftriaxone
A) AMR POCT for ciprofloxacin resistance only. Infections identified as not resistant to ciprofloxacin are given oral ciprofloxacin 
(500 mg) plus ceftriaxone (500 mg). Infections identified as ciprofloxacin resistant are given SC.
B) Dual AMR POCT for azithromycin and ciprofloxacin resistance. If no azithromycin resistance is identified, SC is given. If 
azithromycin resistant, ciprofloxacin (500 mg) and ceftriaxone (500 mg) are given unless there is ciprofloxacin resistance, in which 
case ceftriaxone (500 mg) is given alone.
C) Dual AMR POCT for ciprofloxacin and azithromycin resistance. If no ciprofloxacin resistance is identified, ciprofloxacin (500 
mg) and ceftriaxone (500 mg) are given. If ciprofloxacin resistant, SC is given, unless there is also azithromycin resistance, when 
ceftriaxone (500 mg) is given alone.
Monotherapy optimisation
D) AMR POCT for azithromycin resistance. If no azithromycin resistance is identified, azithromycin (2 g) is given. If azithromycin 
resistant, ceftriaxone (500 mg) and ciprofloxacin (500 mg) dual therapy is given. If the AMR POCT incorrectly shows no resistance 
(false negative for AMR), it is assumed the treatment fails. The treatment failure would be identified in the test-of-cure and the 
patient would then receive 500 mg ceftriaxone.
E) AMR POCT for ciprofloxacin. If no ciprofloxacin resistance is identified, 500 mg ciprofloxacin monotherapy is given. If 
ciprofloxacin resistant, SC is given. If the AMR POCT incorrectly shows no resistance, monotherapy is assumed to fail, the patient 
returns and receives 500 mg ceftriaxone alone.
AMR: amtimicrobial resistance; POCT: point-of-care test; SC: standard care.
3www.eurosurveillance.org
of a second antibiotic alongside ceftriaxone (dual ther-
apy), or enable a single antibiotic alternative to ceftri-
axone (monotherapy) (Box and Table 1).
 The rationale for dual therapy strategies is based on 
the assumption that combination therapy is more effec-
tive at preventing emergence or spread of AMR and 
thereby preserves the use of ceftriaxone. The rationale 
for the monotherapy strategies is that an AMR POCT 
enables effective treatment of the known resistance 
profile, sparing the use of ceftriaxone [22].
Each strategy consisted of a series of intended treat-
ment regimens, contingent on the results of the AMR 
POCT used. For example, in strategy B, the earliest 
intended treatment regimen was SC, where the AMR 
POCT indicated azithromycin resistance; the second 
intended treatment regimen was ceftriaxone and cipro-
floxacin, where the AMR POCT then indicated ciproflox-
acin resistance; the third intended treatment regimen 
was ceftriaxone monotherapy.
A decision tree model was constructed using TreeAge 
Pro version 2017 (TreeAge Software, Williamstown, 
United States (US)) to simulate a hypothetical cohort 
of 38,870 NG-diagnosed SHC attendees (21,915 men 
who have sex with men (MSM), 8,488 women and 
8,467 men who have sex with women (MSW)), repre-
senting the total number of NG diagnoses in England 
SHC in 2015, obtained from the genitourinary medi-
cine clinical activity dataset national surveillance data 
(GUMCAD) [23]. Our assumptions regarding AMR POCT 
use meant the model could not be used when consid-
ering presumptive treatment, e.g. for sexual contacts 
of NG-positive patients initially negative by microscopy 
but subsequently positive by nucleic acid amplifica-
tion testing (NAAT). Approximately 10% of individuals 
diagnosed with NG are in contacts [24] but the epide-
miological breakdown of these patients (e.g. women, 
MSW, MSM) and the nature of their NG diagnoses 
(e.g. microscopy negative and NAAT positive) is not 
reported. Therefore, contacts could not be removed 
from the hypothetical cohort.
Key model assumptions include: 100% compliance with 
test protocols; all patients entering the model are NG 
true-positives; dual AMR POCT results are available 
simultaneously; and there is no ceftriaxone resistance 
data (supported by England’s GRASP [1]) so patients 
with monotherapy treatment failure would return and 
be successfully treated with ceftriaxone only. Model 
assumptions are provided in Supplementary Table S1.
Outcomes
We aimed to assess the costs and effectiveness of 
these AMR POCT strategies to optimise treatment 
regimen choice and reduce selection pressure on cef-
triaxone. The primary outcomes were the total costs 
(2015/16 GBP(EUR)), the percentage of people given 
optimal treatment, and the percentage of people given 
non-ceftriaxone optimal treatment. Optimal treatment 
was defined as one which cured NG and did not con-
tain an antibiotic against which there was resistance. 
Model definitions are provided in Supplementary Table 
S2. These data were used to calculate incremental 
cost-effectiveness ratios (ICER, see equation) for the 
cost per additional optimal treatment gained and the 
cost per additional ceftriaxone treatment avoided. 
This was chosen as the measure of cost-effectiveness 
rather than other measures, such as cost per Quality 
Adjusted Life Years (QALY), because little data exist on 
the consequence of optimal vs suboptimal NG treat-
ment on long-term outcomes, such as mortality or life-
time costs.
A: standard care; B: antimicrobial resistance point-of-
care test strategy; ICER: incremental cost-effectiveness 
ratio.
ICERs were calculated for two types of effective-
ness: optimal treatments and ceftriaxone treatments 
avoided.
Secondary outcomes were the percentage of people 
given a missed earlier intended treatment regimen 
(MEITR), and the percentage of people failing treatment 
due to resistance. MEITR was defined as the use of a 
treatment regimen which cured NG, but where an ear-
lier intended treatment regimen would have provided 
optimal treatment because susceptible infections had 
been misclassified as resistant by the AMR POCT. 
MEITRs were independent of treatment effectiveness.
Treatment
AMR POCT strategy treatment regimens were devel-
oped with input from three senior clinicians at St 
George’s University Hospitals NHS Foundation Trust, 
London, who outlined current and hypothetical AMR 
POCT patient pathways (Supplementary Figure S1). 
The purpose of the work was to determine AMR POCT 
strategy for short-term clinical impacts, because 
these are the data used for sexual health service pro-
visioning and decisionmaking for adoption into SHC 
[18]. Furthermore, progression to longer-term clinical 
impacts from suboptimally treated infection is poorly 
defined [25]. Therefore, the time horizon was that of 
initial patient treatment. Complications associated 
with STIs, such as pelvic inflammatory disease (PID) in 
women, and adverse drug events associated with treat-
ment were not considered.
Model parameters
Model epidemiology parameters are presented in Table 
2, and cost parameters in  Table 3  and  Supplementary 
Table S3. The hypothetical AMR POCT sensitivity and 
specificity were based on other NAAT-based rapid and 
POC tests [26-28], and altered in sensitivity analyses. 
Antibiotic resistance prevalences were obtained from 
national surveillance of SHC attendees (GRASP, 2017) 
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[29]. GRASP is England’s national sentinel surveil-
lance system that detects and monitors AMR in NG and 
records potential treatment failures. As the time hori-
zon was that of initial patient treatment, discounting 
rates were not applied.
A micro-costing approach was employed, consider-
ing only costs incurred to the healthcare provider (i.e. 
SHC). Costs to those procuring sexual health services 
provision, or to health systems as a whole, were not 
considered. Costs were estimated by adapting an exist-
ing model [30] and included: laboratory equipment; 
POCTs and antibiotics; AMR POCTs; and NG treatment 
implementation (e.g. staff time and consumables, 
including partner notification and health promotion) 
(Supplementary Table S3). It was assumed the AMR 
POCTs produced results in 30 min (maximum accept-
able POCT run-time for service users [31,32]) and 
that in all strategies, NG-positive samples would still 
be sent to the laboratory for culture and phenotypic 
resistance testing. Costs are given in 2015/16 prices 
(GBP (EUR)) and inflated when based on old estimates 
[33]. Antibiotic prices were extracted from the British 
National Formulary (BNF) website (September 2016), 
with the cheapest formulation being used including 
non-proprietary costs where available [34]. Initial costs 
of diagnosing NG were not considered as people only 
entered the model after an NG diagnosis. The cost of 
implementing a change to clinical practice was also not 
considered.
Sensitivity analyses
We conducted one-way analyses using TreeAge Pro ver-
sion 2017 (TreeAge Software) and R software version 
3.5.0 (R Foundation, Vienna, Austria), for each of the 
model parameters by varying them independently at 
the ends of their ranges to examine the effect on the 
primary outcome (Table 2). These analyses identified 
which model parameters results were most sensitive 
to. Each sensitivity analysis compared one of the five 
AMR POCT strategies with SC, across three population 
groups (women, MSW, and MSM). Probabilistic sen-
sitivity analyses (PSA) were not performed because 
our analysis was a cost-effectiveness analysis with 
the outcome as cost per event avoided, rather than a 
cost acceptability or cost utility analysis exploring the 
likelihood that the technology is cost-effective at dif-
ferent willingness to pay (WTP) thresholds. There is no 
commonly agreed WTP for our outcome, and therefore 
presenting PSA results would likely not have yielded 
additional beneficial information.
This report was written following the Consolidated 
Health Economic Evaluation Reporting Standards 
(CHEERS) checklist [35].
Ethical statement
As the only data included for this study were nationally 
published surveillance data from PHE, and no patient 
data were used, ethical approval was not required.
Results
Overall AMR POCT strategy costs, treatments used, and 
treatment outcomes compared with SC in all groups are 
presented in Table 4. Breakdowns by population group 
are presented in Supplementary Tables S4, S5 and S6.
Costs
The cost of SC NG management was GBP 2,856,168 
(EUR 3,819,524) for the total cohort (Table 4). All AMR 
POCT strategies cost more than SC, with dual therapy 
AMR POCT strategies more expensive than monother-
apy strategies. Strategy D was the least expensive AMR 
POCT strategy, costing GBP 3,271,684 (EUR 4,375,189), 
14.5% more than SC. Strategy B was the most expen-
sive, costing GBP 4,093,844 (EUR 5,474,656), 43% 
more than SC. This was consistent across all popula-
tion groups (Supplementary Tables S4, S5 and S6).
Table 1
Summary of antimicrobial point-of-care test strategies
Strategy
Antibiotic(s) for which 
 
resistance is tested
Intended treatment regimen based on test result
A + B No resistance to A Resistance to A Resistance to A + B
Strategy A Ciprofloxacin NA NA Ciprofloxacin  + Ceftriaxone Azithromycin   + Ceftriaxone NA
Strategy B Azithromycin  + Ciprofloxacin Azithromycin   + Ceftriaxone Ciprofloxacin  + Ceftriaxone Ceftriaxone
Strategy C Ciprofloxacin  + Azithromycin Ciprofloxacin  + Ceftriaxone Azithromycin   + Ceftriaxone Ceftriaxone
Strategy D Azithromycin NA NA Azithromycina,b NA NA Ciprofloxacin  + Ceftriaxone NA
Strategy E Ciprofloxacin NA NA Ciprofloxacinb NA NA Azithromycin   + Ceftriaxone NA
Standard care No resistance testing is done. Standard care is ceftriaxone 500 mg and azithromycin 1 g dual therapy [6].
NA: not applicable.
a Dose given: 2 g.
b If incorrect test result and treatment fails, ceftriaxone is given.
Bold font indicates standard care antibiotics, i.e. azithromycin and ceftriaxone dual therapy.
Unless otherwise stated, doses are: ceftriaxone 500 mg; azithromycin 1 g; ciprofloxacin 500 mg.
5www.eurosurveillance.org
Optimal treatment
All AMR POCT strategies provided more optimal treat-
ments than SC, in all population groups. Strategy B 
provided most optimal (n  =  38,822) and least subop-
timal (n  =  48) treatments. Strategies A and E equally 
provided the least optimal treatments and the most 
suboptimal (n  =  813) (see  Table 4  and  Supplementary 
Tables S4, S5 and S6).
Ceftriaxone-sparing treatments given
Since all dual therapy strategies used ceftriaxone, only 
monotherapy strategies provided ceftriaxone-sparing 
options. Strategy D reduced ceftriaxone use by 95% 
compared with SC (Table 4).
MEITRs given
A MEITR refers to a treatment regimen being used when 
an earlier intended treatment regimen would have pro-
vided optimal treatment. In all population groups, the 
fewest were in Strategies A and E (n  =  265), and B 
(n  =  267), and the most were in Strategy C (n  =  912) 
(Table 4, Supplementary Tables S4, S5 and S6).
Treatment failures
There were some treatment failures in each mono-
therapy strategy due to false-susceptible AMR POCT 
results: strategy D had 34/38,870 (0.09% of treat-
ments) and Strategy E had 248/38,870 (0.64% of treat-
ments) (Table 4). There were no treatment failures with 
SC or dual therapy strategies (A, B and C) because they 
all included ceftriaxone. This was consistent across all 
population groups (Supplementary Tables S4, S5 and 
S6).
Cost-effectiveness analysis
The cost-effectiveness analysis (CEA) results are pre-
sented in  Table 5. When avoidance of suboptimal 
treatments was considered, Strategy D was most 
cost-effective relative to SC, costing GBP 414.67 (EUR 
554.53) per optimal treatment gained. Strategy A was 
least cost-effective overall, whereas Strategy B was 
the most-cost effective dual therapy strategy.
When avoidance of ceftriaxone use was considered, 
Strategy D was most cost-effective relative to SC, cost-
ing GBP 11.29 (EUR 15.09) per ceftriaxone-sparing treat-
ment gained. These findings were consistent across all 
population groups.
Sensitivity analyses
In one-way sensitivity analyses, the following four 
parameters had the greatest impact on cost-effective-
ness per optimal treatment gained for all AMR POCT 
strategies and across all population groups: preva-
lence of azithromycin resistance; AMR POCT sensitiv-
ity; prevalence of ciprofloxacin resistance; and the cost 
of single detection AMR POCT. In monotherapy strate-
gies, the cost-effectiveness model was additionally 
sensitive to cost of clinical management (both with and 
without injection), cost of ceftriaxone, and AMR POCT 
specificity (for strategy D). The cost multiplier for a 
dual detection AMR POCT impacted on AMR POCT cost-
effectiveness for Strategies B and C. Tornado plots 
from these analyses are presented in  Supplementary 
Figure S2.
For all strategies, variation of ICER in relation to azithro-
mycin resistance prevalence was minimal until preva-
lence fell to or below 3%, at which point it increased 
(Supplementary Figure S3). These rises in ICER were 
least for strategies B and D. With the exception of 
strategy B where ICER were consistent for all popula-
tion groups, these increases in ICER were most limited 
in women.
Variation in AMR POCT accuracy also showed simi-
lar patterns across all population groups. Apart from 
Strategy D, variation in specificity had very little effect 
on cost per optimal treatment gained. In contrast, as 
Table 2






































1 Initial clinic attendances 56.4 NA 21.8 NA 21.8 NA 21,915 NA 8,488 NA 8,467 NA
GUMCAD, 
2015 [23]
2 Resistance to azithromycina 4.7 3.3–6.1 2.7 1.9–3.5 5.3 3.7–6.9 1,030 723–1,337 229 161–297 449 313–584
GRASP, 2017 
[29]
3 Resistance to ceftriaxone 0 0–0 0 0–0 0 0–0 0 0–0 0 0–0 0 0–0
GRASP, 2017 
[29]





5 Sensitivity of AMR POCT 98 90–100 98 90–100 98 90–100 NA NA NA NA NA NA Assumption
6 Specificity of AMR POCT 99 90–100 99 90–100 99 90–100 NA NA NA NA NA NA Assumption
AMR: antimicrobial resistance; GUMCAD: genitourinary medicine clinical activity dataset; GRASP: gonococcal resistance to antimicrobial surveillance programme; MSM: men who have 
sex with men; MSW: men who have sex with women; NA: not applicable; POCT: point-of-care test; W: women.
a The azithromycin resistance ranges were extended further to 1–10% for all population groups in one-way azithromycin resistance analysis so that the effect of more extreme values could 
be explored.
b The ciprofloxacin resistance ranges were extended further to 0–50% in one-way ciprofloxacin resistance analysis so that the effect of more extreme values could be explored.
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sensitivity decreased to a minimum of 90%, particu-
larly towards the lower range, the cost per optimal 
treatment gained increased exponentially, except for 
strategy B where the relationship was linear. Strategy 
B also had the smallest change in ICER between 
maximum (100%) and minimum (90%) sensitivity 
(maximum difference of GBP 169.21 (EUR 226.28) per 
optimal treatment gained in women) compared with 
other strategies where the difference was in the thou-
sands. For Strategy D, change in sensitivity had little 
impact on cost per optimal treatment gained, whereas 
when specificity decreased to below around 95.5%, the 
cost per optimal treatment gained started to increase 
exponentially. The sensitivity analyses are presented 
in Supplementary Figure S4.
The prevalence of ciprofloxacin resistance had very 
little effect on cost per optimal treatment gained in 
Strategies B, C and D (Supplementary Figure S5). For 
Strategies A and E, as ciprofloxacin resistance increased 
from ca 20%, there was an exponential increase in cost 
per optimal treatment gained for women only.
The relationship between ICER and cost of a single tar-
get AMR POCT was linear. Interestingly, as the cost of 
the single target AMR POCT increased, the two dual-
target AMR POCTs diverged, with strategy B costing 
less per optimal treatment gained relative to strategy 
C.
For the three single target AMR POCTs (A, D and E), 
reducing the cost of the test had the greatest impact 
Table 3




Base case value Range (low–high)
Management of NG (oral 
medication/IM injection)






GBP 37.10–68.90 / GBP 
43.92–81.56 
 
(EUR 49.6–92.1 / EUR 
58.73–109.07)
bAdapted from previous model. Adams, 2014 [30]
























Estimate – 10% more than price of single AMR POCT 








Estimate – single AMR POCT is varied, multiplier 


































AMR: antimicrobial resistance; BNF: British National Formulary; IM: intramuscular; NG: Neisseria gonorrhoeae; POCT: point-of-care test.
a GBP costs were converted to EUR using a historic currency conversion of an average of 366 days from 1 July 2015 to 30 June 2016 [48]. For 
this time period, GBP 1 = EUR 1.34, and EUR 1 = GBP 0.75.
b Includes staff time and consumables but not antibiotic costs. Costs were inflated to 2015/16 costs using the Hospital and Community Health 
Services (HCHS) Inflation Indices 2015 produced by the Personal Social Services Research Unit [33]. No data were available for inflation 
from 2014/15 to 2015/16 so it was assumed to be the same as between 2013/2014 and 2014/15. The United Kingdom hospital consumer 
price index for health services shows similar annual growth in this sector from 2014 (93.2 in 2013, 97.1 in 2014 and 100 in 2015), which 
validates this assumption [49]. GBP costs were converted to EUR using a historic currency conversion of an average of 366 days from 1 
July 2015 to 30 June 2016 [48]. For this time period, GBP 1 = EUR 1.34, and EUR 1 = GBP 0.75. A further breakdown of cost data are provided 
in Supplementary Table S3.
c Within the context of this model, treatment failure due to resistance to a monotherapy would result in a return visit. No repeat culture 
would be taken and no repeat diagnostic tests would occur. The patient would be successfully treated using ceftriaxone, administered via 
injection.
d Oral medication.
e  Administered via intramuscular injection. The price quoted is for 1 g vial of ceftriaxone, the smallest non-proprietary vial available [34] - the 
remaining 500 mg is then discarded.
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on cost per treatment gained. Monotherapy strate-
gies became cost-saving (ICER <  0) for all population 
groups when AMR POCT cost was ≤ GBP 18 (24.07 EUR) 
for Strategy D, and ≤  GBP 16 (EUR 21.40) for Strategy 
E (Supplementary Figure S6). Strategy B had lowest 
costs per additional optimal treatment for dual therapy 
strategies.
Discussion
We assessed the cost-effectiveness and impacts of 
deploying AMR POCTs for  N. gonorrhoeae.  All AMR 
POCT strategies assessed resulted in more optimal 
treatments compared with SC. Monotherapy AMR POCT 
strategies provided ceftriaxone-sparing options, with 
Strategy D reducing the use of ceftriaxone by 95%. 
Both outcomes are important in promoting antibiotic 
stewardship by minimising risks of breakthrough with 
ceftriaxone-resistant circulating strains, and reducing 
selection pressure for resistance developing to 
ceftriaxone, respectively.
Our cost-effectiveness analysis adapted a previously 
published cost-effectiveness model of introducing a 
dual CT/NG POCT into a SHC [28,30], and was popu-
lated using available published data, and where una-
vailable, using unpublished data and expert opinion. 
By employing a decision tree model approach we could 
account for sufficient complexity without over-build-
ing. However, this approach is, in contrast to using a 
transmission dynamic model [36], unable to assess 
outcomes such as the impact AMR POCTs could have 
on re-infection in a previously treated patient, on pop-
ulation prevalence or burden of disease, or on AMR 
evolution.
Turner et al. have adapted the same CT/NG POCT cost-
effectiveness model we used for our analysis [28,30] 
to analyse the potential clinical and overall economic 
impact of an NG AMR POCT [37]. While theirs was not 
a cost-effectiveness analysis, and different model 
assumptions and parameters from ours were used, 
they also demonstrated that AMR POCTs could lead to 
overall reductions in ceftriaxone use, but that intro-
duction of AMR POCTs incurred increased costs. Using 
an individual-based dynamic transmission model that 
incorporated partner treatment and which was applied 
to a London MSM population, Zienkiewicz et al. [38] 
also demonstrated that AMR POCTs for NG ciprofloxacin 
sensitivity reduced ceftriaxone use, by 70% compared 
with the reference scenario. An individual-based model 
of molecular NG AMR test use compared with culture 
within an NG surveillance system in remote settings 
Table 4
Total costs, treatments used and treatment outcomes for standard care and antimicrobial resistance point-of-care test 
strategies: all groups (n = 38,870)
Strategy Total costa















38,870 38,870 0 37,162 1,708 NA NA






38,870 12,408 26,462 38,057 813 265 NA







38,870 36,825 1,373 38,822 48 267 NA







38,870 11,736 26,462 38,611 259 912 NA






2,080 36,825 2,045 38,164 706 372 34






12,656 12,408 26,462 38,057 813 265 248
AMR: antimicrobial resistance; MEITR: missed earlier intended treatment regimen; NG: Neisseria gonorrhoeae; POCT: point-of-care test.
a GBP costs were converted to EUR using a historic currency conversion of an average of 366 days from 1 July 2015 to 30 June 2016 [48]. For 
this time period, GBP 1 = EUR 1.34 , and EUR 1 =  GBP 0.75.
b ‘Optimal’ refers to a treatment regimen which cures the NG infection and does not contain any antibiotic against which there is resistance.
c ‘Suboptimal’ refers to a treatment regimen which contains antibiotics against which there is NG resistance - if the treatment is a 
monotherapy it will result in treatment failure.
d ‘Missed earlier intended treatment regimen’ (MEITR) refers to a treatment regimen which cures the NG infection and does not contain any 
antibiotic against which there is resistance, but a treatment regimen was used when an earlier intended treatment regimen would have 
provided optimal treatment – a MEITR is due to a false-resistant AMR POCT result.
e ‘Treatment failure’ refers to failure to cure an NG infection due to resistance to an antibiotic given as monotherapy and is due to a false-
susceptible AMR POCT result.
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Table 5
Cost effectiveness analysis for standard care and antimicrobial resistance point-of-care test strategies
Subgroup Comparison Total additional costa
Additional cost 
per patienta
Number of optimal 
treatments gained





















































































































































































































































































AMR: antimicrobial resistance; MSM: men who have sex with men; MSW: men who have sex with women; POCT: point-of-care test; SC: 
standard care.
a GBP costs were converted to EUR using a historic currency conversion of an average of 366 days from 1 July 2015 to 30 June 2016 [48]. For 
this time period, GBP 1 = EUR 1.34, and EUR 1 = GBP 0.75.
A strategy is ‘dominated’ if it is more expensive and provides fewer/equivalent benefits.
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found that they substantially improved the timeliness 
of NG AMR detection, facilitating a faster change in rec-
ommended treatment, with potential for decreasing NG 
AMR impact on the wider population [39]. Fingerhuth 
et al. [36] developed a compartmental transmission 
model of antibiotic-sensitive and antibiotic-resistant 
NG to look at proportion of resistant infections and 
cases averted. They showed that the clinical pathway 
that included an AMR POCT resulted in the lowest pro-
portion of resistant infections after 30 years, whereas 
the clinical pathway with a POCT that did not test for 
AMR resulted in the highest. They also noted that test 
diagnostic performance is key for AMR POCTs to have 
a beneficial public health impact. The potential public 
health impact of AMR POCTs was confirmed by Tuite 
et al., with AMR POCTs delaying the proportion of iso-
lates reaching > 5% resistance compared with empirical 
treatment [40]. However, it was highlighted that the 
AMR POCT should test for resistance to multiple aniti-
microbials, otherwise non-tested, resistant, strains will 
be selected for. Thus, continued surveillance, including 
culture, should be continued. Together, these health 
economic and modelling evaluations highlight the pos-
sible beneficial impacts of implementing AMR POCTs 
on reducing ceftriaxone use and decreasing NG AMR 
prevalence at the population level, but the design and 
implementation of the tests should also be carefully 
considered.
As with all mathematical models, several assumptions 
were made (Supplementary Table S1), including AMR 
POCT diagnostic accuracy - a necessity as these tests 
are currently in early phases of development [16,41]. 
Future performance estimates will need to consider 
two elements: predictive accuracies of any biomarkers 
used to detect AMR; the performance of platforms and 
chemistries used to detect them. Variations in both 
may independently affect outcomes.
Our analysis had some limitations. We used the most 
recent NG AMR data available from GRASP at the time 
[29], but AMR rates constantly change and, in the 
sensitivity analyses, AMR prevalence alterations had 
the greatest impact on AMR POCT cost-effectiveness 
(Supplementary Figure S2). This may limit the gener-
alisability of our results as it is not possible to know 
future resistance profiles. However, the results should 
be generalisable to the ranges used in the sensitiv-
ity analyses. In addition, as AMR POCTs are still in 
development, some of the model’s other epidemio-
logical parameters will have changed by the time the 
AMR POCTs are available for use in routine practice, 
which may further limit the analyses’ applicability in 
the longer term. This highlights the need to continually 
conduct analyses such as these, to enhance our abil-
ity to predict and understand future trends. Our anlay-
ses are also limited to data from England, with results 
perhaps less generalisable to other countries. This will 
be exacerbated by the 2019 change to 1 g ceftriaxone 
monotherapy, further setting it aside from guidelines 
in other European countries [7]. Our model also did not 
consider NG-positive patients coinfected with another 
organisms, such as CT, which would affect patient 
pathways and treatment options. Additional factors not 
considered were costs associated with treating long-
term NG infection sequelae [42], costs incurred outside 
of the SHC, and costs or cost-savings associated with 
changing clinical pathways in order to accommodate 
the AMR POCTs. Thus the time horizon for the costs 
and consequences was of initial patient treatment only.
Strategy B was most effective for avoiding suboptimal 
treatments but the most costly to implement. Strategy 
D was the most cost-effective for both effectiveness 
outcomes (optimal treatments gained and ceftriaxone 
avoidance), but resulted in treatment failures, as well 
as nearly 15-fold higher suboptimal treatments com-
pared with Strategy B. Both strategies B and D enabled 
the re-use of ciprofloxacin, previously abandoned for 
the treatment of NG in the UK [6].
All AMR POCT strategies were more expensive than SC, 
with dual therapy AMR POCT strategies more expensive 
than monotherapy strategies, suggesting that short-
term net financial investments in AMR POCT adoption 
are required to gain long-term antimicrobial steward-
ship benefits. The O’Neill review of AMR [10] noted that 
accepting the initial expense of new test introduction 
may enable longer-term societal pay-offs by reducing 
infection rates and maintaining effective NG treat-
ments. Interestingly, our sensitivity analysis suggested 
that even if AMR POCT costs were notably reduced, 
perhaps through production scale-up, dual therapy 
AMR POCT strategies would still not be cost-saving. 
However, a relatively small reduction to less than GBP 
18 (EUR 24.07) per test would enable the monotherapy 
AMR POCT strategies to be cost-saving.
The monotherapy strategies resulted in treatment 
failures due to false susceptible AMR POCT results, 
although minimal relative to SC. Since we assumed 
ceftriaxone treated 100% of NG infections, there were 
no treatment failures for SC or dual therapy strategies. 
The most recent GRASP data suggest that ceftriax-
one resistance remains low (no ceftriaxone resistance 
reported, although there is a reduction in susceptibil-
ity with 24.6% of isolates with minimum inhibitory con-
centrations (MICs) ≥ 0.03 mg/L in 2018 compared with 
16.6% in 2017 [1]), but there are increasing concerns 
regarding international ceftriaxone-resistant strains 
[43-45]. This potentially undermines our assumption 
and the resulting lack of treatment failures from dual 
therapy AMR POCT strategies.
Most MEITRs (treatment regimen used when an ear-
lier intended treatment regimen would have provided 
optimal treatment) were in Strategy C, and the least 
in Strategies A, B and E. Avoiding MEITRs is important 
because it maximises the ability to use ciprofloxacin 
(in Strategies A, C and E), or reduces the need for cef-
triaxone use (Strategies B and D). These numbers were 
small compared with actual patient numbers in whom 
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a MEITR might be used if these AMR POCTs were avail-
able more generally. For example, using national sur-
veillance data [23,46], we estimated that over 25,000 
of the 38,870 NG-diagnosed SHC patients assumed 
to have been treated with SC in 2015 would have had 
ciprofloxacin-susceptible NG. Strategies A and E would 
have enabled all, except 265 (Table 4), of these patients 
to be treated with ciprofloxacin, a 100-fold reduction in 
these missed opportunities.
Since a MEITR is due to susceptible infections misclas-
sified as resistant by the AMR POCT, test specificity 
is key. In sensitivity analyses of AMR POCT accuracy, 
Strategy D was the only strategy where cost per optimal 
treatment gained was affected by changes in specific-
ity. In all other strategies, cost per optimal treatment 
gained increased as sensitivity decreased. This is 
because these strategies contained an AMR POCT that 
included ciprofloxacin testing, so resistance (20–36%, 
dependent on population group [29]) was detected and 
optimal treatment could be given. In contrast, if AMR 
POCT sensitivity in these strategies fell, true cipro-
floxacin-resistant cases were missed and the patient 
suboptimally treated. Strategy D, where the AMR POCT 
was for azithromycin only, was the only strategy where 
ciprofloxacin was given without resistance-testing - 
as the specificity decreased, more patients received 
false-positive azithromycin resistance results and were 
treated with ciprofloxacin. Due to high ciprofloxacin 
resistance prevalence, this treatment was subopti-
mal in a large number of cases. Following the logic of 
the other strategies, if azithromyin resistance preva-
lence increased, cost per optimal treatment gained in 
Strategy D would become sensitive to both AMR POCT 
specifity and sensitivity.
Thus, prevalence of resistance has important impli-
cations for AMR POCT accuracy requirements and 
ICER of optimal treatments gained. In the azithromy-
cin resistance sensitivity analyses, ICER increased 
when resistance fell below ca 3% (well below current 
UK azithromycin resistance prevalence, reported at 
ca 9.7% [1]), primarily because when azithromycin 
resistance is low, there is little value in testing for it 
(Strategies B, C and D) and there will be few treatment 
failures from background resistance (Strategies A and 
E). In the ciprofloxacin resistance sensitivity analysis, 
an effect on ICER was only seen in women in strategies 
A and E (because of lower baseline ciprofloxacin resist-
ance prevalence).
From a population-level antimicrobial stewardship 
public health perspective, increasing the number 
of suboptimal treatments may eventually lead to an 
increased number of resistant infections [36]. The rela-
tive public health importance of a smaller total num-
ber of suboptimal treatments with a few treatment 
failures vs a higher number of suboptimal treatments 
with no failures warrants further investigation, and 
could be included in future transmission model analy-
ses. Furthermore, the long-term public health impact 
of preserving ceftriaxone use while increasing the risk 
of treatment failures from monotherapy strategies (vs 
maintaining ceftriaxone in the earlier intended treat-
ment regimen with an increase in suboptimal treat-
ments and no adequate treatment alternative), should 
also be investigated.
Conclusion
Once developed, AMR POCTs could have wide-rang-
ing implications for clinical decisionmaking globally, 
including the potential re-use of antibiotics previously 
abandoned for the treatment of NG, ensuring the right 
treatment is given to the right person at the right time 
(precision medicine). Although it may be necessary to 
accept net health system investment to enable longer-
term societal pay-offs by reducing infection rates and 
maintaining effective NG treatments, a relatively small 
reduction in test cost could enable some AMR POCT 
strategies to be cost-saving.
empirical study and modelling is required to optimise 
their use for public health benefit.
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